Table e2. Baseline characteristics, visual function scores, QOL scores, and MRI metrics of patients in the AFFIRM trial.

Characteristics	N	Mean±SD	Median	Min	Max
Age (years)	942	36±8.3	37	18	50
VFT					
HCVA (100%) (0-60)	942	56.2±8.1	59	0	60
LCVA (2.5%) (0-60)	941	34.2±11.5	37	0	57
LCVA (1.25%) (0-60)	941	26.4±12.9	29	0	55
QOL					
SF-36 PCS score (50±10)	906	43.9±10.1	45.2	18	65.9
SF-36 MCS score (50±10)	906	46.1±10.9	48.2	11.7	68.6
IVIS* score (0-15)	358	1.3±2.3	0	0	15
VAS score (0-100)	932	67.2±20.9	70.5	0	100
MRI					
T1-hypointense lesion volume (mm^3)	939	5732.5±8011.8	2720	0	88869

T2-lesion volume (mm^3)	939	15,405.0±16,724.4	9637	0	140276
Gd+ lesion volume (mm^3)	939	353.2±822.0	0	0	9667
BPF value	925	0.8±0.02	0.8	0.7	0.9
No. Gd+ lesions	939	2.2±4.7	0	0	39
EDSS score	942	2.3±1.2	2.0	0	6.0

*Subset of English-speaking patients. BPF: brain parenchymal fraction; EDSS: Expanded Disability Status Scale; Gd+: gadolinium enhancing; HCVA: high-contrast visual acuity; IVIS: Impact of Visual Impairment Scale; LCVA: low-contrast visual acuity; MCS: Mental Component Summary; PCS: Physical Component Summary; QOL: quality of life; SD: standard deviation; SF-36: Short Form-36; VAS: visual analogue scale; VFT: visual function testing.